{"generic":"Secukinumab","drugs":["Cosentyx","Secukinumab"],"mono":{"0":{"id":"931337-s-0","title":"Generic Names","mono":"Secukinumab"},"1":{"id":"931337-s-1","title":"Dosing and Indications","sub":[{"id":"931337-s-1-4","title":"Adult Dosing","mono":"<ul><li>Evaluate patients for TB (tuberculin skin test) prior to therapy; do not administer if active infection. Treatment of active or latent TB infection should be started prior to secukinumab therapy.<\/li><li><b>Plaque psoriasis (Moderate to Severe), In patients who are candidates for systemic therapy or phototherapy:<\/b> Initial, 300 mg (2 injections of 150 mg) SUBQ at weeks 0, 1, 2, 3, and 4; some patients may only need 150 mg<\/li><li><b>Plaque psoriasis (Moderate to Severe), In patients who are candidates for systemic therapy or phototherapy:<\/b> Maintenance, 300 mg (2 injections of 150 mg) SUBQ every 4 weeks; some patients may only need 150 mg<\/li><\/ul>"},{"id":"931337-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},{"id":"931337-s-1-6","title":"Dose Adjustments","mono":"<b>Infection:<\/b> Interrupt therapy until resolution "},{"id":"931337-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Plaque psoriasis (Moderate to Severe), In patients who are candidates for systemic therapy or phototherapy<br\/>"}]},"3":{"id":"931337-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931337-s-3-9","title":"Contraindications","mono":"Hypersensitivity to secukinumab or any component of this product <br\/>"},{"id":"931337-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Exacerbation of Crohn's disease, sometimes serious, has been reported; exercise caution in and closely monitor patients with active Crohn's disease<\/li><li>Immunologic:<\/li><li>-- Infections have been reported, with an increased risk with increasing dose; monitoring recommended and discontinuation may be required if serious infection develops<\/li><li>-- Use caution in patients with chronic infection or a history of recurrent infection<\/li><li>-- Tuberculosis; do not administer to patients with active infection, treat latent TB prior to initiating secukinumab, and monitor for infection during treatment<\/li><li>-- Anaphylaxis and urticaria have been reported; discontinue if anaphylaxis or serious allergic reaction occur<\/li><li>-- Latex allergy; cap contains natural rubber latex<\/li><li>-- Completion of all age-appropriate vaccinations prior to treatment initiation is recommended<\/li><li>Concomitant use:<\/li><li>-- Avoid live vaccine administration during treatment<\/li><\/ul>"},{"id":"931337-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"931337-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931337-s-4","title":"Drug Interactions","sub":{"1":{"id":"931337-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (theoretical)<\/li><li>Adenovirus Vaccine Type 7, Live (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Aminophylline (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Measles Virus Vaccine, Live (theoretical)<\/li><li>Mumps Virus Vaccine, Live (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Poliovirus Vaccine, Live (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Rotavirus Vaccine, Live (theoretical)<\/li><li>Rubella Virus Vaccine, Live (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Smallpox Vaccine (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Typhoid Vaccine (theoretical)<\/li><li>Varicella Virus Vaccine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Yellow Fever Vaccine (theoretical)<\/li><\/ul>"}}},"5":{"id":"931337-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (2.6% to 4.1%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (11.4% to 12.3%), Upper respiratory infection (2.5% to 3.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Crohn's disease, Exacerbation (0.09%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Infectious disease (Up to 12 weeks, 28.7%; up to 52 weeks, 47.5%)<\/li><\/ul>"},"6":{"id":"931337-s-6","title":"Drug Name Info","sub":{"0":{"id":"931337-s-6-17","title":"US Trade Names","mono":"Cosentyx<br\/>"},"2":{"id":"931337-s-6-19","title":"Class","mono":"<ul><li>Antipsoriatic<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"931337-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931337-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931337-s-7","title":"Mechanism Of Action","mono":"Secukinumab is a human IgG1 monoclonal antibody that inhibits the release of proinflammatory cytokines and chemokines by selectively binding to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor, a naturally occurring cytokine involved in normal inflammatory and immune responses.<br\/>"},"8":{"id":"931337-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"931337-s-8-23","title":"Absorption","mono":"Bioavailability, SubQ: 55% to 77% <br\/>"},"3":{"id":"931337-s-8-26","title":"Excretion","mono":"Total body: 0.14 L\/day to 0.22 L\/day <br\/>"},"4":{"id":"931337-s-8-27","title":"Elimination Half Life","mono":"22 to 31 days <br\/>"}}},"9":{"id":"931337-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Lyophilized powder, reconstitution: Healthcare professional use only; takes about 20 minutes to reconstitute but should not take more than 90 minutes; prepare the required number of vials (1 vial for the 150 mg dose or 2 vials for the 300 mg dose); inject 1 mL of room temperature sterile water; tilt vial 45 degrees and gently rotate for 1 minute; do not shake or invert vial; allow 10 minutes for dissolution; gently rotate vial for another minute; allow to stand undisturbed for 5 minutes; final concentration is 150 mg\/mL<\/li><li>Lyophilized powder: Following reconstitution, use immediately or within 24 hours if stored in refrigerator<\/li><li>Sensoready(R) pen or prefilled syringe: the removable cap contains natural rubber latex and should not be handled by latex-sensitive individuals<\/li><li>Allow to reach room temperature (15 to 30 minutes) before injecting; administer within 1 hour after removing from refrigerator<\/li><li>Sensoready(R) pen or prefilled syringe: Discard any unused product<\/li><li>Administer each injection at a different anatomic location (eg, upper arms, thighs, or any quadrant of abdomen) than the previous injection; avoid areas where skin is tender, bruised, erythematous, indurated, or affected by psoriasis<\/li><\/ul>"},"10":{"id":"931337-s-10","title":"Monitoring","mono":"<ul><li>Tuberculosis infection; before, during, and after treatment.<\/li><li>Exacerbation of Crohn disease; patients with active Crohn disease.<\/li><\/ul>"},"11":{"id":"931337-s-11","title":"How Supplied","mono":"<b>Cosentyx<\/b><br\/>Subcutaneous Solution: 150 MG\/ML<br\/>"},"13":{"id":"931337-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of infection.<\/li><li>Side effects may include nasopharyngitis, upper respiratory tract infection, or diarrhea.<\/li><li>Instruct patient to avoid live vaccinations during therapy.<\/li><li>Teach patient proper technique and placement of injections.<\/li><\/ul>"}}}